Incidental pancreatic cyst and IPMN surveillance

ACR Incidental Findings pancreatic cyst white paper; European and Kyoto IPMN guidelines

A surveillance question rather than a diagnostic one, and one where the modality choice is driven by what the follow-up costs over a decade. Two features decide almost everything — communication with the duct and the presence of an enhancing mural nodule — and MRI shows both better than CT.

A pancreatic cystic lesion found on imaging performed for another reason, or an established cyst under surveillance.

Referenced decision support — confirm against your local protocol.

Decision support, not a directive. Protocols and timings shown are typical published ones — your local protocol takes precedence, and the vetting radiologist decides.

The request in front of you

Everything is optional. Leave a field alone and the answer assumes nothing — the verdict updates as you go.

Study requested

What the referrer actually asked for. It is evidence of intent, not a constraint on the right answer.

Contrast as written

What the request form says, not what it should say.

Age

Pick a band, or type an exact age if it matters.

years

Pregnancy status

Known cancer

Back pain in a cancer patient is a different question, and staging phase changes which contrast phases are needed.

Renal risk factors

The question a vetter can actually answer from the request. An explicit “none known” is a real answer, and it removes checks rather than deferring them.

Previous contrast reaction

The pathway — tap anything already done

Marking a study complete moves the answer on. A patient arrives partway through a pathway far more often than at the start of one.

Accept as requested

MRI Pancreas — dynamic contrast-enhanced with MRCP

MRI Pancreas

What we'd amend, and why

Two features carry the risk, and MRI resolves both. Heavily T2-weighted cholangiographic sequences show the thin channel connecting a side-branch cyst to the main duct, which CT usually cannot resolve, and they show internal septations that CT renders as homogeneous fluid. Dynamic gadolinium then distinguishes an enhancing mural nodule, which is the strongest single predictor of malignancy, from non-enhancing mucin or debris that looks identical on any unenhanced study. Because this lesion will be imaged repeatedly for years, doing it without ionising radiation is a decision about cumulative dose as much as about image quality.

Nothing needs resolving before this goes ahead. Routine checks below are owned downstream.

How was this decided?

pathwayadult — Adults
rulerule-mr-device-screening — MR safety screening for implants and foreign bodies; checked by Radiographer at the scanner
rulerule-contrast-reaction-premed — Prior contrast reaction and elective premedication; checked by Nurse before the scan
rulerule-gadolinium-renal — Kidney function and gadolinium-based contrast; checked by Radiographer at the scanner
rulerule-pregnancy-gadolinium — Gadolinium in known or possible pregnancy; checked by Radiographer at the scanner
rulerule-iv-access — Intravenous access adequate for the planned injection; checked by Radiographer at the scanner

Decision support only. Local protocol takes precedence.

Handled at the scanner(2)nothing for you to do

Settled and owned downstream. Each returns to a radiologist only on the stated trigger.

MR safety screening for implants and foreign bodies
Complete the MR safety questionnaire, verify implant labelling and its stated conditions of use against this scanner and this protocol, and ensure no ferromagnetic object enters Zone IV.
Radiographer at the scannerBefore the scan
Flags back if: An implant or retained foreign body that is MR Unsafe, unlabelled, or cannot be identified; or an MR Conditional device whose stated conditions this scanner or the requested protocol cannot satisfy; or a credible unexcluded intraocular metallic foreign body history.
Intravenous access adequate for the planned injection
Site and test a cannula that supports the protocol flow rate, preferring an antecubital or large forearm vein, and observe the injection for extravasation. A 20-gauge or larger cannula is preferred for flow rates of 3 mL/s or more.
Radiographer at the scannerAt the scanner
Flags back if: No cannula can be sited that supports the protocol flow rate — for example only a 22-gauge hand or foot cannula for a CT angiogram needing 4–5 mL/s; or the only available access is a central line or port that is not labelled power-injectable; or an extravasation occurs.

Pathways

Big forks are separate pathways; the first whose conditions match is the one used.

Established cyst under interval surveillance

Role	Study & protocol	Why this answers the question
First line	MRCP (MR Cholangiopancreatography) MRCP — standard unenhanced usually appropriate	Surveillance asks three measurable things — has the cyst grown, has the main duct changed, has anything new appeared — and heavily T2-weighted cholangiographic sequences answer all three without an injection. The gadolinium on a diagnostic study is there for one purpose, to separate an enhancing mural nodule from non-enhancing mucin, and that question is not being asked at a routine interval visit in a lesion with no worrisome features. Leaving it out shortens the appointment, avoids an unnecessary cannula, and avoids repeated gadolinium exposure across a schedule that may run for a decade or more. The condition attached is explicit: if the cyst has grown, if the main duct has dilated, if a nodule or a solid component is suspected on the unenhanced sequences, or if the patient is newly jaundiced, the study converts to the contrast-enhanced protocol at that visit rather than at the next one.
Second line	MRI Pancreas MRI Pancreas — dynamic contrast-enhanced with MRCP	The contrast study is the escalation, not the routine. It is the right acquisition at the visit where something has changed — measurable growth, a new or enlarging mural nodule, main duct dilatation, a new solid component, or new jaundice — because the enhancing nodule is the single strongest predictor of malignancy and cannot be confirmed on unenhanced sequences, where mucin and debris look identical to it.

Consistency beats resolution in surveillance: the same modality, the same sequence and the same measurement plane every time, because the decision is driven by change and a modality switch manufactures apparent growth.
Endoscopic ultrasound with aspiration is the other escalation and is not an imaging alternative to it — it is what answers the question when the cross-sectional appearances remain equivocal.

Adults

Matches your inputsDefault

Role	Study & protocol	Why this answers the question
First line	MRI Pancreas MRI Pancreas — dynamic contrast-enhanced with MRCP usually appropriate	Two features carry the risk, and MRI resolves both. Heavily T2-weighted cholangiographic sequences show the thin channel connecting a side-branch cyst to the main duct, which CT usually cannot resolve, and they show internal septations that CT renders as homogeneous fluid. Dynamic gadolinium then distinguishes an enhancing mural nodule, which is the strongest single predictor of malignancy, from non-enhancing mucin or debris that looks identical on any unenhanced study. Because this lesion will be imaged repeatedly for years, doing it without ionising radiation is a decision about cumulative dose as much as about image quality.
Reasonable alternative	MRCP (MR Cholangiopancreatography) MRCP — standard unenhanced	For routine interval surveillance of a stable cyst with no worrisome features, an unenhanced cholangiographic study measures size, duct calibre and cyst number, which is all the surveillance decision needs. It is faster, cheaper and avoids repeated gadolinium exposure across many years, and contrast can be added at the visit where something changes.
Second line	CT Pancreas Protocol CT Pancreas — Dual Phase with Water Distension	Where MRI is contraindicated or unavailable, or where a worrisome feature has appeared and the question has become resectability, a dual-phase pancreatic CT gives tumour conspicuity and vascular contact. Its weakness for this indication is exactly the two features that matter: duct communication and small mural nodules.

European guidance lists jaundice, an enhancing mural nodule above about 5 mm and a main pancreatic duct above about 10 mm as absolute indications for surgical referral; other frameworks phrase their thresholds differently, so the report should describe the features and leave the threshold to the multidisciplinary team.

Pitfalls

Following the cyst with repeated contrast-enhanced CT. It exposes a patient with a probably indolent lesion to years of radiation while resolving duct communication less well than MRI.
Injecting gadolinium at every surveillance visit. Size, duct calibre and cyst number are unenhanced measurements; contrast answers the mural nodule question and belongs to the visit where something has changed, not to the schedule.
Surveilling a patient who should have stopped, or one who was never a candidate for intervention. Surveillance is only justified while the patient would be fit for and would accept resection, and the decision to stop is part of the pathway rather than an omission from it.
Calling every unilocular cyst a pseudocyst without asking about a pancreatitis history, or every septated cyst a mucinous neoplasm without considering a serous lesion.
Mistaking non-enhancing mucin or a mucin ball for a mural nodule, which is precisely why the enhanced sequences exist.
Reporting growth from measurements taken on different modalities or in different planes.
Overlooking main duct dilatation adjacent to the cyst, which is a far more concerning feature than the size of the cyst itself.

Priors — what to pull first

Find the earliest study on which the cyst is visible, even one performed for an unrelated reason. Documented stability over several years is the strongest argument against intervention and often shortens the surveillance schedule.
Measure at the same location and in the same plane as the previous report; inconsistent measurement is the commonest cause of a spurious growth alert.

What makes a good request

Guidelines from different bodies do not agree on size thresholds, surveillance intervals or when to stop, so the local multidisciplinary policy governs and the report should state which framework it is using.
Communication with the pancreatic duct is what identifies a side-branch intraductal papillary mucinous neoplasm and separates it from a serous or mucinous cystic lesion, which have different natural histories.

Scoring this once it is done

The classification and risk tools this question ends in.

RECIST 1.1 Tumor Response

How these studies are acquired

Contrast, phases and timing for every study on the pathways above.

MRCP — standard unenhanced MRI Pancreas — dynamic contrast-enhanced with MRCP CT Pancreas — Dual Phase with Water Distension

Confirm locally

MRI Pancreas — dynamic contrast-enhanced with MRCP: timings are typical — confirm against local protocol.
Timings, contrast volumes and rates above are typical published values. Your department's protocol, scanner and patient population decide the actual numbers.
Safety thresholds and premedication policy follow local policy where it differs from the cited guidance.

References

Implemented from the cited published sources. Educational and workflow support only; confirm against current guidelines and local policy before clinical use.